Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
0.00%
)
Bitcoin
68,656.00
(
-0.34%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

io_io

Send PM Follow Ignore
Followers 63
Posts 5557
Boards Moderated 0
Alias Born 01/17/2005

io_io

Re: DewDiligence post# 17513

Thursday, 10/27/2005 2:52:33 PM

Thursday, October 27, 2005 2:52:33 PM

Post# of 257268
first-line and off-label:

Am curious about this - is it perfectly logical that Erbitux be second-line (to chemo I presume), or is this a consequence of the clinical trial process in that it is difficult to displace the SoC due to ethical concerns..........

I mean it's not that Erbitux is 2nd-best to anything in CRC ?

"....on the biotech battle-field, you need some élan...."

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today